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The outlook for many patients with acute lymphoblastic leukemia (ALL) has
continued to improve but the increasing number of surviving children created
the question whether biological cure goes with good quality of life. Chronic
side-effects of disease and/or treatment may impede cognitive and
psychosocial development and therefore also hinder children from meeting
academic demands. In children with ALL, particularly concern has emerged
on the iatrogenic effects of central nervous system (CNS) prophylaxis,
essential though it was to improve survival. This thesis dealt with the late and
persistent neuropsychological sequelae of 3 successive national DCLSGT
protocols ALL 5, ALL 6 and ALL 7 with different forms of CNS prophylaxis.
Accumulating evidence of cognitive decline in children treated on protocol
ALL 5 with cranial inadiation (CI) and chemotherapy subsequently sparked
investigations on cognitive functioning in children treated with
chemotherapy-only (protocols ALL 6 and ALL 7). Patients on any protocol
were longitudinally studied by means of repeated neuropsychological
assessments (NPA), magnetic resonance imaging (MRI) of the brain and
evaluation of school career. We focused on the younger age group (diagnosis
< 7 years of age) considering the greater wlnerability of the immature brain
for diffuse (radiation induced) damage. Patients in this study were mainly
treated at the Children's Cancer Center, University Hospital of Groningen and
diagnosed between 1979 and 1992.
The medical background of the patients under study was given in chapter
one. Incidence, pathogenesis, treatment and outcome of ALL were briefly
described. Noteworthy, survival has increased from 50 to 75Yo from the late-
seventies to the mid-nineties (all risk groups combined).
Dutch Childhood Leukemia Study Group
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chapter two was a case report. This child, treated on DCLSG protocol ALL
5 at a young age, represented the group of patients who are at risk for the
deleterious effects of CI and intrathecal (IT) and intravenous (IV)
methotrexate (MTX) on brain functioning. At age 15, this cured girl
contended with moderate difficulties in the domains of attention, arithmetic,
executive and fine motor functioning besides low-normal intelligence. At age
20, the sequelae of these cognitive deficits had resulted in major vocational
problems which clearly and persistently found expression in her first job, l5
years after treatment.
Chapter three summarized an extensive review of the neuropsychological
and related literature with special focus on research methodology that may
explain the still contradictory results. In pediatric neuropsychology, test shift
seems one of the most difficult and almost insurmountable bottlenecks for
longitudinal research.
we discussed the possible relationships among risk factors, etiology and
specificity of cognitive impairment. There is no doubt that administration of
cI (with MTX) is associated with mild to moderate global cognitive
deterioration in young children. The plasticity of the immature brain can
apparently not sufficiently compensate for diffuse damage acquired at an
early age. The relative contribution of chemotherapy penetrating into the CNS
is not yet unequivocal. The complex background of this field of research was
further illustrated by discussing the neuropathology underlying the occurrence
of cognitive decline. Both a necrotizing leuco-encephalopathy and a
mineralizing micro-angiopathy have been widely reported in inadiated
children but the relationship between neuroradiological and
neuropsychological measures remains unclear. We subsequently described the
acute and early but transient effects of neurotoxic treatment on mental status.
Such effects, like psychological problems, may interfere with optimal
cognitive development but must be distinguished from the late and persistent
sequelae of leukemia treatment. This chapter ended with placing the ALL
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patients in a wider context of children and adults with brain tumors who are
treated with considerably higher doses of CI.
Patients' characteristics, treatment protocols, study design, instruments,
hypotheses and statistical analyses were described in chapter four.
From 1981 to 1988, 35 consecutive children treated for ALL according the
DCLSG protocol ALL 5 or the Groningen High Risk protocol (CI +
chemotherapy) were enrolled in this study. They had 2 NPA's after cessation
of two years chemotherapy. Median age at diagnosis was 3;5 years, median
age at the first NPA was 6;4 years and median age at the second NPA was
I 1;4 years.
From 1986 to 1990,17 consecutive patients treated on DCLSG protocol ALL
6 (chemotherapy-only) entered the study. They also has 2 NPA's after
completion of 2 years treatment. Median age at diagnosis was 3;5 years,
median age at the first NPA was 5;10 years and median age at the second
NPA was 9;3 years.
Between 1988 and 1992,20 consecutive patients treated on DCLSG protocol
ALL 7 (also chemotherapy-only) entered a prospective study. A first NPA
was performed prior to CNS prophylaxis to obtain a cognitive 'baseline'.
Moreover, we wished to investigate the feasibility of examining young
children shortly after diagnosis. Then, they had 2 more NPA's after lYz or 2
years chemotherapy according to the schedule for protocol ALL 5 and ALL 6
patients. Median age of diagnosis and first assessment was 3;6 years, median
age at the second evaluation was 5;3 and median age at the last examination
was 10;3 years.
Longitudinal participation for the combined study group (n:65) was 92oÁ.
The aim of this series of studies was to evaluate a broad domain of cognitive
functioning. Assessments included measures of verbal and performance
intelligence, auditory learning and memory, sustained attention and
attentional capacity, visual motor integration and fine motor functioning
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(yielding 12 psychometric measures in protocol ALL 5 and protocol ALL 6
and 14 measures in protocol ALL 7, at the last assessments). Patients' test
performance was compared to healthy peers from the same geographical area.
Moreover, protocol ALL 5 patients were compared to children on protocol
ALL 6 and the DCLSG protocol ALL 6 group in turn was compared to
patients on protocol ALL 7. Additionally, poor performance was determined
per test and per each case individually, defined as a standard score at least
1,64 SD below the normative mean for that specific test (representing the
lowest 50Á of the norm population). Tests with a (predominantly) motor
output were distinguished from tests mainly measuring cognition.
An MRI of the brain was scheduled in the year after the second NPA for
every patient if aged > 5 years, and compared to psychometric findings. MRI
scans were judged normal, probably abnormal or definitely abnormal from 3
types of abnormalities: atrophy, calcifications and signal abnormalities as
index for white matter damage. MRI scans could be obtained in 50 cases
(89% of the eligible subjects). MRI findings in protocol ALL 5 patients were
compared to protocol ALL 6 who were then compared to children treated on
protocol ALL 7 .
In the late-nineties, school career was evaluated in all patients by
questionnaire developed for the neuropsychological research in our
institution. Parents reported on possible placements in special primary
schools for learning disabled (in Dutch: LOM and MLK schools) and on level
of secondary education. These levels were classified through a 6 points scale.
Category one was lowest representing special education for children with
defective IQ's (in Dutch: VSO-MLK), category four was the mean level for
the Netherlands (in Dutch: MAVO) and category six was the highest level
preparing for university (in Dutch: VWO). Median follow-up since diagnosis
was 13 years for the DCLSG protocol ALL 5 group, near 9 years for DCLSG
protocol ALL 6 patients and ample 7 years for subjects treated on DCLSG
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compared to their healthy siblings (n:98). Participation was l0A% in ever
study group.
Later, a nationwide study was designed in ALL survivors diagnosed at any
age and treated according to DCLSG protocol ALL 5. The school
questionnaire was completed by 94 patients and their 134 siblings
(participation rate 64%). Median age at evaluation was 20 years and median
follow-up since diagnosis was 15 years.
Hypotheses stated lower test scores and school levels in any patient group,
compared to healthy controls and siblings, respectively (one tailed testing).
Moreover, we expected higher test scores and school levels and less MRI
abnormalities for patients treated on protocol ALL 6 with chemotherapy-only
compared to irradiated children on protocol ALL 5 (one tailed testing). It was
hypothesized that MRI abnormalities would correspond with poorer test
performance in any patient group. Younger age at diagnosis and higher CI
dose (18 versus 25 Gy in protocol ALL 5 only) were considered risk factors
for poorer outcome but female sex was not.
We could study change over time by comparing test results from successive
evaluations but we did not specifically expect either improvement or decline
(two tailed testing). Only results from the same tests were used for
longitudinal comparisons.
Lastly, we were interested in a possible different outcome for either protocol
ALL 6 and ALL 7 (both chemotherapy-only) but no specific hypothesis was
formulated (two tailed testing). Protocol ALL 6 contained higher cumulative
doses of dexamethasone, vincristine and it treatment but on the other hand,
protocol ALL 7 was the more intensive treatment.
Emphasis was on the results of the last NPA's, as young age at the first
evaluations and test shift would limit the numbers of comparisons for the first
assessments. We calculated effect size and 95% confidence intervals. To
correct for the high numbers of comparisons, significance levels were
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reported at p < 0.004 (Bonferroni correction). In our articles however, usual
levels of p < 0.05 were also given.
Results were shown in chapters five through nine.
Chapter Íive described the control group, composed as norrn group for new
test versions of Rey's auditory verbal learning test (RAVLT). This test is one
of the most widely used and relevant word learning and memory tests for
children and adults but adequate normative data for Dutch children were still
lacking. Moreover, parallel forms were needed to avoid practice effects in a
repeated measurements design. We collected normative data for the existing
form of the RAVLT and 2 newly constructed parallel forms in a sample of
225 Dutch school children. Except for the use of this study, these test forms
have proved very useful in the daily practice of pediatric neuropsychology.
Chapter six offered psychometric test data of the second NPA and MRI
findings in 35 children treated at a young age on DCLSG protocol ALL 5 (CI
* chemotherapy), including 7 cases with meningeal leukemia. Main purpose
of this study was to compare neuroradiological and neuropsychological
results, with 8 years follow-up since diagnosis. Results showed that MRI's
were classified as definitely abnormal in 5loÁ and as probably abnormal in
another l7%o of the patients. White matter damage was most frequently seen.
MRI abnormalities were not related to sex, CI dose, age at diagnosis and test
performance. Patients had significantly lower scores, compared to the norïn
group on measures of intelligence, short term memory and visual and frne
motor functioning. Some lower test scores significantly correlated with
younger age (diagnosis < 4 years versus > 4 years) or higher CI dose (25 - 32
Gy compared to 18 - 20 Gy) but not with meningeal leukemia as such. Forry
percent of the patients had to be referred to schools for learning disabled. We
concluded that ALL treatment including CI and chemotherapy at a young age
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In Chapter seven school career was evaluated in 94 long term survivors,
treated with CI and chemotherapy according to DCLSG protocol ALL 5 at
any age in comparison to their 134 siblings (a nationwide study).
Results showed that significantly more patients than siblings (n: L2 versus n
: 1) were placed in special primary schools. Mean level of secondary
education in the patients was also signihcantly lower than in siblings (level
3.4 versus 4.5 respectively; 4 was the mean level for the Netherlands). But,
the majority of patients was not mentally retarded and it was questioned
whether the 1. 1 point difference is clinically important. No effect of gender or
CI dose (25 Gy versus 18 Gy) was found. In contrast, younger age at
diagnosis was strongly related to both more referrals to special primary
education and lower final educational evel. Only in patients diagnosed at an
age > 7 yearc, no significant differences were found in comparison to
siblings. We concluded that treatment for childhood ALL at a young age with
either 18 or 25 Gy CI and chemotherapy was clearly associated with poorer
academic career.
Chapter eight, offered all results in 17 subjects treated at a young age
according to DCLSG protocol ALL 6 with chemotherapy-only. At the last
NPA (median follow-up 5 years after diagnosis), patients performed
significantly worse than controls on measures of auditory memory and fine
motor functioning. Considering individual cases, 17 patients combined
performed poorly on 16 measures, 9 motor scores included. Seven cases had
at least one below-average score on a cognitive test but only one child had a
low (verbal) IQ. MRI scans could be obtained in 16 subjects; probably
abnormal scans were found in three and definitely abnormal scans in another
three children (combined 38% abnormality), but abnormalities did not
correlate with.lower test scores. Seventeen patients and their 33 siblings did
not significantly differ in school placements and levels. These nonirradiated
protocol ALL 6 patients demonstrated significantly higher verbal IQ's, better
attentional capacity, less learning disability and less MRI abnormalities than
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28 ALL 5 patients (excluding 7 cases with meningeal leukemia). On an
individual level, 28 subjects on protocol ALL 5 performed poorly on 56
measures, 25 motor scores included. Eleven children had at least one below-
aveÍage score on a cognitive test and 5 subjects had a low verbal or
performance IQ. We concluded: (l) treatment on protocol ALL 6 may be
associated with some cognitive impairment compared to controls but
fortunately these children reach school levels equal to their siblings so far; 2)
protocol ALL 6 patients demonstrated better cognitive functioning and less
MRI abnormalities than the irradiated children on protocol ALL 5.
In chapter nine we reported all results for 20 children treated at a young age
on DCLSG protocol ALL 7 with chemotherapy-only. We found no
developmental delay at the start of therapy in a subset of 14 patients who
were old enough to complete the Wechsler Intelligence test and Beery test of
visual motor integration. Moreover, it proved feasible to perform such
examinations shortly after diagnosis. At the last NPA (median follow-up 7
years since diagnosis) significantly lower scores for patients in comparison to
controls were found for one attention measure only. Considering individual
cases, 20 patients combined performed poorly on24 measures, 5 motor scores
included. Ten children had at least I below-average score on a cognitive test
and 2 subjects had an low verbal or performance IQ. MRI scans could be
obtained in l0 subjects; one MRI was unevaluable, probably abnormal scans
were found in two cases but no definitely abnormal scans were found
(combined 22oÁ abnormality). No great differences were seen between school
achievement in 20 patients and their 17 siblings. We concluded that (1)
children treated on protocol ALL 7 had no major cognitive impairment and
(2) the slightly better outcome for ALL 7 patients in comparison to protocol
ALL 6 (on memory and attention tasks) may indicate possible adverse effects
of more dexamethasone and it treatment in the latter. The addendum of
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Chapter ten offered a general discussion and conclusions. First, we described
the ideal prospective-longitudinal study on neuropsychological sequelae in
children treated for leukemia. Unfortunately, young age for the majority of
ALL patients leads to major conceptual and methodological bottlenecks. It
was a challenge to design and initiate a multicenter prospective study in
newly diagnosed patients aged 4 to 12 treated on the current DCLSG protocol
ALL 9. This study, including sibling controls and applying a comprehensive
test battery started in 1998 and will continue until 4 years follow-up is
reached. In this ongoing study, special attention will be paid to attentional and
memory skills as most sensitive test measures in the previous series of
studies. Next, we discussed the limitations and strengths of our research.
Small numbers reduced the power to detect possible differences, if any,
between patient groups and controls and among subgroups of patients at risk.
Strengths included a standardized longitudinal design and high participation
rates of representative study groups. Subsequently, we returned to our
hypotheses. It was confirmed that irradiated patients (protocol ALL 5)
suffered more cognitive impairment than controls and nonirradiated children.
In contrast, it was not confirmed that children treated with chemotherapy-
only would still show significantly poorer performance across the whole test
battery than controls.
Slight differences between both chemotherapy groups (ALL protocol 6 and 7)
tentatively supported evidence that corticosteroids may affect cognitive
functioning.
According to our hypothesis, lower age at diagnosis was associated with
poorer test performance in irradiated children only. Many other studies also
revealed a clear age effect with cognitive disabilities more apparent in
children irradiated with 18 - 25 Gy below the age of 5 to 7 years which is
congruent with the susceptibility of the immafure brain to systemic
pathological influences. As expected, MRI abnormalities (white matter
damage, atrophy and calcifications) were most often found in inadiated
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children. We have tried to relate cognition to anatomy in order to identify the
structural damage underlying the neuropsychological deficits in ALL
survivors. However, test results and school achievements were not related to
MRI findings, rejecting our hypothesis. To counsel individual patients who
experience deficits in school or vocational life, neuropsychological
assessments eem more essential than MRI examinations.
Contrary to some other studies, we did not find an additional adverse effect of
female gender in any study group. Another risk factor, which could not be
tested as such, emerged from clinical experience: Pre-existing
psychopathology seemed to invigorate cognitive disabilities, if present. We
therefore need to offer prompt additional support to such children who
manifest with mental or behavioral disfurbances.
Test performance remained mostly stable after cessation of chemotherapy in
all study groups with no significantly decline as suggested by other
investigators. However, we don't know yet what may happen to brains after
exposure to irradiation or chemotherapy in the very long term. So far,
children treated on chemotherapy protocol ALL 6 and protocol 7 have
reached normal levels of secondary education but slight memory or attention
disturbances may result in vocational handicaps much later in life.
The discussion was closed with a look into the future of the child treated for
leukemia. Our results may be reassuring for patients who did not receive Cl
but we still need to develop intervention programs for the few individuals
who do experience cognitive disability. Results of individual assessments
have already been employed to implement remedial teaching programs.
Psychologists must participate in late effects clinics to evaluate eventual job
success or failure, among other things.
Thus, neuropsychology in pediatric oncology centers must serve several
goals: (l) individual (neuro)psychological assessment for those patients who
experience difficulties or mental deficits which may be related to disease and
treatment; (2) intervention and counseling based on such individual
diagnostic procedures; (3) continued availability in late effects clinics with


































the purpose of timely detection of possible cognitive deterioration in the long
term and (4) evaluation of the neurotoxicify of treatment by which
neuropsychology can contribute to the development of new protocols yielding
best survival with optimal quality of life.
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